A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Glioblastoma Multiforme
Both
Glioblastoma Multiforme
Trial Information
A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma
Inclusion Criteria:
- Adults patients, >/= 18 years of age
- Histologically confirmed glioblastoma multiforme in first or second relapse
Exclusion Criteria:
- Patients not qualifying for Avastin treatment as per local label
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival at 6 months
Outcome Time Frame:
approximately 3 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Taiwan: Taiwan Food and Drug Administration
Study ID:
ML25550
NCT ID:
NCT01618747
Start Date:
May 2013
Completion Date:
May 2015
Related Keywords:
- Glioblastoma Multiforme
- Glioblastoma
Name | Location |
|---|
